St. Baldrick’s Foundation shared on LinkedIn:
“Exciting news on the horizon for sarcoma patients from researchers at Baylor College of Medicine! The latest HEROS 2.0 trial using CAR T-cells targeting HER2 protein has shown safety and clinical benefit, with 50% of patients seeing positive results. With continued research and multiple infusions, we’re seeing huge potential for long-term cancer-free outcomes.
Learn more about this research that was partially funded by St. Baldrick’s.”